Antihormonal-Treatment Status Affects 68 Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Kilian Kluge und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) is known to influence the prostate-specific membrane antigen (PSMA) expression of prostate cancer, potentially complicating the interpretation of PSMA ligand PET findings and affecting PSMA radioligand therapy. However, the impact of ADT on PSMA ligand biodistribution in nontumorous organs is not well understood.
Methods
Men (n = 112) with histologically proven prostate cancer who underwent 68Ga-PSMA-HBED-CC (68Ga-PSMA-11) PET/CT between November 2015 and July 2021 at the Medical University Vienna with known ADT status were retrospectively recruited. Fifty-six patients were on gonadotropin-releasing hormone-interfering ADT at the time of imaging (ADT group), whereas 56 patients with no history of ADT served as a control group. Physiologically PSMA-expressing organs (salivary glands, kidneys, liver, and spleen) were delineated, and their uptake was compared according to their data distributions. Multivariate regression analysis assessed the relationship between renal, hepatic, splenic, and salivary gland uptake and the explanatory variables metabolic tumor volume, glomerular filtration rate, and ADT status.
Results
ADT was associated with lower levels of PSMA uptake in the kidneys (SUVmean: Δ[ADT - control] = -7.89; 95% CI, -10.73 to -5.04; P < 0.001), liver (SUVpeak: Δ[ADT - control] = -2.3; 95% CI, -5.72 to -0.93; P = 0.003), spleen (SUVpeak: Δ[ADT - control] = -1.27; 95% CI, -3.61 to -0.16; P = 0.033), and salivary glands (SUVmean: Δ[ADT - control] = -1.04; 95% CI, -2.48 to -0.13; P = 0.027). In a multivariate analysis, ADT was found to be associated with lower renal (SUVmean: β = -7.95; 95% CI, -11.06 to -4.84; P < 0.0001), hepatic (SUVpeak: β = -7.85; 95% CI, -11.78 to -3.91; P < 0.0001), splenic (SUVpeak: β = -5.83; 95% CI, -9.95 to -1.7; P = 0.006), and salivary gland (SUVmean: β = -1.47; 95% CI, -2.76 to -0.17; P = 0.027) uptake. A higher glomerular filtration rate was associated with a higher renal SUVmean (β = 0.16; 95% CI, 0.05 to 0.26; P = 0.0034).
Conclusion
These findings suggest that ADT systemically modulates PSMA expression, which may have implications for treatment-optimizing and side-effect-minimizing strategies for PSMA radioligand therapies, particularly those using more potent 225Ac-labeled PSMA conjugates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
- Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria.
- QIMP Team, Medical University of Vienna, Vienna, Austria.
- Department of Pathology, Medical University of Vienna, Vienna, Austria.
- Department of Urology, Medical University of Vienna, Vienna, Austria.
- Department of Urology and Andrology, University Hospital Krems, Krems, Austria.
Zitieren
APA
Kluge, K., Haberl, D., Einspieler, H., Rasul, S., Gutschmayer, S., Kenner, L., Kramer, G., Grubmüller, B., Shariat, S., Haug, A., & Hacker, M. (2023). Antihormonal-Treatment Status Affects 68 Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265980
Vancouver
Kluge K, Haberl D, Einspieler H, Rasul S, Gutschmayer S, Kenner L, et al. Antihormonal-Treatment Status Affects 68 Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265980
BibTeX
@article{Kluge2023,
author = {Kluge, Kilian and Haberl, David and Einspieler, Holger and Rasul, Sazan and Gutschmayer, Sebastian and Kenner, Lukas and Kramer, Gero and Grubmüller, Bernhard and Shariat, Shahrokh and Haug, Alexander and Hacker, Marcus},
title = {Antihormonal-Treatment Status Affects 68 Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265980}
}
EUVIMED